Calidi eliminates CLO role; W. Pizarro Campbell departs Oct 17, 2025

Calidi Biotherapeutics, Inc.

CLO position eliminated; Campbell's employment terminated Oct 17, 2025 as part of cost-reduction initiatives; no disagreement cited.
Campbell receives severance of $212,500 paid over six months, plus potential $85,000 bonus tied to Nova Cell transaction before Oct 31, 2025.
Campbell enters six-month consulting agreement at $250/hr (max 20 hrs/mo) starting Oct 18, 2025.
CFO Andrew Jackson appointed as Corporate Secretary effective Oct 17, 2025.
Separation agreement includes standard release, confidentiality, and non-disparagement clauses.

item 1.01item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.